Key result
Nogo-A blockade enhances post-stroke vascular repair and reduces neurological deficits in mice.
Answers are grounded in this paper and cite their sources.
Stroke is a major cause of serious disability due to the brain's limited capacity to regenerate damaged tissue and neuronal circuits. After ischemic injury, a multiphasic degenerative and inflammatory response is coupled with severely restricted vascular and neuronal repair, resulting in permanent functional deficits. Although clinical evidence indicates that revascularization of the ischemic brain regions is crucial for functional recovery, no therapeutics that promote angiogenesis after cerebral stroke are currently available. Besides vascular growth factors, guidance molecules have been identified to regulate aspects of angiogenesis in the central nervous system (CNS) and may provide targets for therapeutic angiogenesis. In this study, we demonstrate that genetic deletion of the neurite outgrowth inhibitor Nogo-A or one of its corresponding receptors, S1PR2, improves vascular sprouting and repair and reduces neurological deficits after cerebral ischemia in mice. These findings were reproduced in a therapeutic approach using intrathecal anti-Nogo-A antibodies; such a therapy is currently in clinical testing for spinal cord injury. These results provide a basis for a therapeutic blockage of inhibitory guidance molecules to improve vascular and neural repair after ischemic CNS injuries.
No takes yet. Share an insight, caveat, or question.
Rust et al. (2019) studied Cerebral ischemia (stroke). Genetic deletion of Nogo-A/S1PR2 or intrathecal anti-Nogo-A antibodies was evaluated on Vascular sprouting, vascular repair, and neurological deficits. Genetic deletion or therapeutic blockade of Nogo-A via intrathecal antibodies improved vascular sprouting and repair and reduced neurological deficits after cerebral ischemia in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: